Chinese- REPORT SUMMARY
- TABLE OF CONTENTS
-
The worldwide Prophylactic Human Vaccines market was valued at XX.0 Million US$ in 2018 and is projected to reach XX.0 Million US$ by 2026, at a CAGR (Compound Annual Growth Rate) of 9.8% during the forecast period.
This report presents the market size and development trends by detailing the Prophylactic Human Vaccines market revenue, market share and growth rate from 2015-2026, and it gives a thorough analysis by various product types, applications, regions, and main participants. The market conditions (2015-2019), corporate competition pattern, corporate SWOT analysis are elaborated, and other qualitative analyses like market dynamics, market penetration, market business environment analyses, the regional regulatory scenario in the Prophylactic Human Vaccines market will be shown in this report. In short, this report will comprehensively reveal the characteristics of Prophylactic Human Vaccines industry and will help you to build a panoramic view of the industrial development.
Prophylactic Human Vaccines Market, By Type:
Type 1
Type 2
Type 3
Prophylactic Human Vaccines Market, By Application:
End-Users 1
End-Users 2
End-Users 3
Some of the leading players are as follows:
BiondVax Pharmaceuticals Ltd. (Israel)
Bavarian Nordic A/S (Denmark)
Hualan Biological Engineering Inc. (China)
Altimmune, Inc (US)
GlaxoSmithKline Plc. (UK)
Serum Institute of India Pvt Ltd (India)
SK Chemicals Co., Ltd. (Korea)
Zydus Cadila (India)
Sanofi Pasteur SA (France)
Shanghai BravoBio Co., Ltd. (China)
Merck & Co., Inc. (US)
BiondVax Pharmaceuticals Ltd (Israel)
Bharat Biotech International Limited (India)
Pfizer Inc. (US)
Altimmune, Inc. (US)
Serum Institute of India Pvt. Ltd. (India)
Hualan Biological Engineering Inc (China)
Janssen Pharmaceuticals, Inc. (US)
Geographically, Major regions are analyzed in details are as follows:
-
North America
-
Europe
-
Asia Pacific
-
Latin America
-
Middle East & Africa
Table of Contents
1 Methodology and Scope
-
1.1 Market Segmentation & Scope
-
1.1.1 Technology Type
-
1.1.2 Product
-
1.1.3 Application
-
1.1.4 Regional scope
-
1.1.5 Estimates and forecast timeline
-
1.2 Research Methodology
-
1.3 Information Procurement
-
1.3.1 Purchased database
-
1.3.2 Internal database
-
1.3.3 Secondary sources
-
1.3.4 Primary research
-
1.3.5 Details of primary research
-
1.4 Information or Data Analysis
-
1.4.1 Data analysis models
-
1.5 Market Formulation & Validation
-
1.6 Model Details
-
1.6.1 Commodity flow analysis
-
1.6.2 Volume price analysis
-
1.7 List of Secondary Sources
-
1.8 List of Abbreviations
2 Executive Summary
-
2.1 Market Outlook
-
2.2 Segment Outlook
3 Market Variables, Trends, & Scope
-
3.1 Market Lineage Outlook
-
3.1.1 Parent market outlook
-
3.1.2 Ancillary market outlook
-
3.2 Market Segmentation
-
3.2.1 Analysis
-
3.3 Market Dynamics
-
3.3.1 Market driver analysis
-
3.3.2 Market restraint analysis
-
3.3.3 Industry opportunities
-
3.4 Penetration & Growth Prospect Mapping
-
3.4.1 Penetration & growth prospect mapping analysis
-
3.5 Business Environment Analysis Tools
-
3.5.1 Porter's five forces analysis
-
3.5.2 PESTLE analysis
-
3.5.3 Major deals & strategic alliances analysis
4 Prophylactic Human Vaccines Market: Technology Type Analysis
-
4.1 Prophylactic Human Vaccines Technology Type Market Share Analysis, 2018 & 2026
-
4.2 Prophylactic Human Vaccines Technology Type Market: Segment Dashboard
-
4.3 Market Size & Forecasts and Trend Analyses, 2015 to 2026 for the Technology Type Segment
4.3.1 Type 1
4.3.2 Type 2
4.3.3 Type 3
5 Prophylactic Human Vaccines Market: Product Analysis
-
5.1 Prophylactic Human Vaccines Product Market Share Analysis, 2018 & 2026
-
5.2 Prophylactic Human Vaccines Product Market: Segment Dashboard
-
5.3 Market Size & Forecasts and Trend Analyses, 2015 to 2026 for the Product Segment
6 Prophylactic Human Vaccines Market: Application Analysis
-
6.1 Prophylactic Human Vaccines Application Market Share Analysis, 2018 & 2026
-
6.2 Prophylactic Human Vaccines Application Market: Segment Dashboard
-
6.3 Market Size & Forecasts and Trend Analyses, 2015 to 2026 for the Application Segment
6.3.1 End-User 1
6.3.2 End-User 1
6.3.3 End-User 3
7 Prophylactic Human Vaccines Market: Regional Analysis
-
7.1 Prophylactic Human Vaccines Regional Market Share Analysis, 2018 & 2026
-
7.2 Prophylactic Human Vaccines Regional Market: Segment Dashboard
-
7.3 Regional Market Snapshot (Market Size, CAGR, Top Countries)
-
7.4 List of Players at Regional Level
-
7.4.1 North America
-
7.4.2 Europe
-
7.4.3 Asia Pacific
-
7.5 SWOT Analysis, by Factor (Political & Legal, Economic and Technological)
-
7.5.1 North America
-
7.5.2 Europe
-
7.5.3 Asia Pacific
-
7.5.4 Latin America
-
7.5.5 MEA
-
7.6 Market Size & Forecasts, and Trend Analysis, 2015 to 2026
-
7.6.1 North America
-
7.6.2 Europe
-
7.6.3 Asia Pacific
-
7.6.4 Latin America
-
7.6.5 Middle East & Africa
8 Competitive Analysis
-
8.1 Recent Developments & Impact Analysis, by Key Market Participants
-
8.2 Strategic Framework/Competition Categorization (Key innovators, Market leaders, Emerging players)
-
8.3 Vendor Landscape
-
8.3.1 Company market position analysis (Geographic presence, service portfolio, strategic initiatives)
9 Company Profiles
9.1 BiondVax Pharmaceuticals Ltd. (Israel)
9.1.1 BiondVax Pharmaceuticals Ltd. (Israel) Company overview
9.1.2 Financial performance
9.1.3 Product benchmarking
9.1.4 Strategic initiatives
9.1.5 SWOT analysis
9.2 Bavarian Nordic A/S (Denmark)
9.2.1 Bavarian Nordic A/S (Denmark) Company overview
9.2.2 Financial performance
9.2.3 Product benchmarking
9.2.4 Strategic initiatives
9.2.5 SWOT analysis
9.3 Hualan Biological Engineering Inc. (China)
9.3.1 Hualan Biological Engineering Inc. (China) Company overview
9.3.2 Financial performance
9.3.3 Product benchmarking
9.3.4 Strategic initiatives
9.3.5 SWOT analysis
9.4 Altimmune, Inc (US)
9.4.1 Altimmune, Inc (US) Company overview
9.4.2 Financial performance
9.4.3 Product benchmarking
9.4.4 Strategic initiatives
9.4.5 SWOT analysis
9.5 GlaxoSmithKline Plc. (UK)
9.5.1 GlaxoSmithKline Plc. (UK) Company overview
9.5.2 Financial performance
9.5.3 Product benchmarking
9.5.4 Strategic initiatives
9.5.5 SWOT analysis
9.6 Serum Institute of India Pvt Ltd (India)
9.6.1 Serum Institute of India Pvt Ltd (India) Company overview
9.6.2 Financial performance
9.6.3 Product benchmarking
9.6.4 Strategic initiatives
9.6.5 SWOT analysis
9.7 SK Chemicals Co., Ltd. (Korea)
9.7.1 SK Chemicals Co., Ltd. (Korea) Company overview
9.7.2 Financial performance
9.7.3 Product benchmarking
9.7.4 Strategic initiatives
9.7.5 SWOT analysis
9.8 Zydus Cadila (India)
9.8.1 Zydus Cadila (India) Company overview
9.8.2 Financial performance
9.8.3 Product benchmarking
9.8.4 Strategic initiatives
9.8.5 SWOT analysis
9.9 Sanofi Pasteur SA (France)
9.9.1 Sanofi Pasteur SA (France) Company overview
9.9.2 Financial performance
9.9.3 Product benchmarking
9.9.4 Strategic initiatives
9.9.5 SWOT analysis
9.10 Shanghai BravoBio Co., Ltd. (China)
9.10.1 Shanghai BravoBio Co., Ltd. (China) Company overview
9.10.2 Financial performance
9.10.3 Product benchmarking
9.10.4 Strategic initiatives
9.10.5 SWOT analysis
9.11 Merck & Co., Inc. (US)
9.11.1 Merck & Co., Inc. (US) Company overview
9.11.2 Financial performance
9.11.3 Product benchmarking
9.11.4 Strategic initiatives
9.11.5 SWOT analysis
9.12 BiondVax Pharmaceuticals Ltd (Israel)
9.12.1 BiondVax Pharmaceuticals Ltd (Israel) Company overview
9.12.2 Financial performance
9.12.3 Product benchmarking
9.12.4 Strategic initiatives
9.12.5 SWOT analysis
9.13 Bharat Biotech International Limited (India)
9.13.1 Bharat Biotech International Limited (India) Company overview
9.13.2 Financial performance
9.13.3 Product benchmarking
9.13.4 Strategic initiatives
9.13.5 SWOT analysis
9.14 Pfizer Inc. (US)
9.14.1 Pfizer Inc. (US) Company overview
9.14.2 Financial performance
9.14.3 Product benchmarking
9.14.4 Strategic initiatives
9.14.5 SWOT analysis
9.15 Altimmune, Inc. (US)
9.15.1 Altimmune, Inc. (US) Company overview
9.15.2 Financial performance
9.15.3 Product benchmarking
9.15.4 Strategic initiatives
9.15.5 SWOT analysis
9.16 Serum Institute of India Pvt. Ltd. (India)
9.16.1 Serum Institute of India Pvt. Ltd. (India) Company overview
9.16.2 Financial performance
9.16.3 Product benchmarking
9.16.4 Strategic initiatives
9.16.5 SWOT analysis
9.17 Hualan Biological Engineering Inc (China)
9.17.1 Hualan Biological Engineering Inc (China) Company overview
9.17.2 Financial performance
9.17.3 Product benchmarking
9.17.4 Strategic initiatives
9.17.5 SWOT analysis
9.18 Janssen Pharmaceuticals, Inc. (US)
9.18.1 Janssen Pharmaceuticals, Inc. (US) Company overview
9.18.2 Financial performance
9.18.3 Product benchmarking
9.18.4 Strategic initiatives
9.18.5 SWOT analysis
The List of Tables and Figures (Totals 64 Figures and 152 Tables)
Figure Type 1 Prophylactic Human Vaccines market, 2015 - 2026 (USD Million)
Figure Type 2 Prophylactic Human Vaccines market, 2015 - 2026 (USD Million)
Figure Type 3 Prophylactic Human Vaccines market, 2015 - 2026 (USD Million)
Figure End-Users 1 market, 2015 - 2026 (USD Million)
Figure End-Users 2 market, 2015 - 2026 (USD Million)
Figure End-Users 3 market, 2015 - 2026 (USD Million)
-
Table List of players in North America
-
Table List of players in Europe
-
Table List of players in Asia Pacific
-
Table SWOT analysis
-
Table North America Prophylactic Human Vaccines market, by country, 2015 - 2026 (USD Million)
-
Table North America Prophylactic Human Vaccines market, by type, 2015 - 2026 (USD Million)
-
Table North America Prophylactic Human Vaccines market, by product, 2015 - 2026 (USD Million)
-
Table North America Prophylactic Human Vaccines market, by application, 2015 - 2026 (USD Million)
-
Table Regulatory scenario
-
Table U.S. Prophylactic Human Vaccines market, by type, 2015 - 2026 (USD Million)
-
Table U.S. Prophylactic Human Vaccines market, by product, 2015 - 2026 (USD Million)
-
Table U.S. Prophylactic Human Vaccines market, by application, 2015 - 2026 (USD Million)
-
Table Regulatory scenario
-
Table Canada Prophylactic Human Vaccines market, by type, 2015 - 2026 (USD Million)
-
Table Canada Prophylactic Human Vaccines market, by product, 2015 - 2026 (USD Million)
-
Table Canada Prophylactic Human Vaccines market, by application, 2015 - 2026 (USD Million)
-
Table Europe Prophylactic Human Vaccines market, by country, 2015 - 2026 (USD Million)
-
Table Europe Prophylactic Human Vaccines market, by type, 2015 - 2026 (USD Million)
-
Table Europe Prophylactic Human Vaccines market, by product, 2015 - 2026 (USD Million)
-
Table Europe Prophylactic Human Vaccines market, by application, 2015 - 2026 (USD Million)
-
Table Regulatory scenario
-
Table U.K. Prophylactic Human Vaccines market, by type, 2015 - 2026 (USD Million)
-
Table U.K. Prophylactic Human Vaccines market, by product, 2015 - 2026 (USD Million)
-
Table U.K. Prophylactic Human Vaccines market, by application, 2015 - 2026 (USD Million)
-
Table Regulatory scenario
-
Table Germany Prophylactic Human Vaccines market, by type, 2015 - 2026 (USD Million)
-
Table Germany Prophylactic Human Vaccines market, by product, 2015 - 2026 (USD Million)
-
Table Germany Prophylactic Human Vaccines market, by application, 2015 - 2026 (USD Million)
-
Table Regulatory scenario
-
Table France Prophylactic Human Vaccines market, by type, 2015 - 2026 (USD Million)
-
Table France Prophylactic Human Vaccines market, by product, 2015 - 2026 (USD Million)
-
Table France Prophylactic Human Vaccines market, by application, 2015 - 2026 (USD Million)
-
Table Regulatory scenario
-
Table Italy Prophylactic Human Vaccines market, by type, 2015 - 2026 (USD Million)
-
Table Italy Prophylactic Human Vaccines market, by product, 2015 - 2026 (USD Million)
-
Table Italy Prophylactic Human Vaccines market, by application, 2015 - 2026 (USD Million)
-
Table Regulatory scenario
-
Table Spain Prophylactic Human Vaccines market, by type, 2015 - 2026 (USD Million)
-
Table Spain Prophylactic Human Vaccines market, by product, 2015 - 2026 (USD Million)
-
Table Spain Prophylactic Human Vaccines market, by application, 2015 - 2026 (USD Million)
-
Table Asia Pacific Prophylactic Human Vaccines market, by country, 2015 - 2026 (USD Million)
-
Table Asia Pacific Prophylactic Human Vaccines market, by type, 2015 - 2026 (USD Million)
-
Table Asia Pacific Prophylactic Human Vaccines market, by product, 2015 - 2026 (USD Million)
-
Table Asia Pacific Prophylactic Human Vaccines market, by application, 2015 - 2026 (USD Million)
-
Table Regulatory scenario
-
Table China Prophylactic Human Vaccines market, by type, 2015 - 2026 (USD Million)
-
Table China Prophylactic Human Vaccines market, by product, 2015 - 2026 (USD Million)
-
Table China Prophylactic Human Vaccines market, by application, 2015 - 2026 (USD Million)
-
Table Regulatory scenario
-
Table Japan Prophylactic Human Vaccines market, by type, 2015 - 2026 (USD Million)
-
Table Japan Prophylactic Human Vaccines market, by product, 2015 - 2026 (USD Million)
-
Table Japan Prophylactic Human Vaccines market, by application, 2015 - 2026 (USD Million)
-
Table Regulatory scenario
-
Table India Prophylactic Human Vaccines market, by type, 2015 - 2026 (USD Million)
-
Table India Prophylactic Human Vaccines market, by product, 2015 - 2026 (USD Million)
-
Table India Prophylactic Human Vaccines market, by application, 2015 - 2026 (USD Million)
-
Table Latin America Prophylactic Human Vaccines market, by country, 2015 - 2026 (USD Million)
-
Table Latin America Prophylactic Human Vaccines market, by type, 2015 - 2026 (USD Million)
-
Table Latin America Prophylactic Human Vaccines market, by product, 2015 - 2026 (USD Million)
-
Table Latin America Prophylactic Human Vaccines market, by application, 2015 - 2026 (USD Million)
-
Table Regulatory scenario
-
Table Brazil Prophylactic Human Vaccines market, by type, 2015 - 2026 (USD Million)
-
Table Brazil Prophylactic Human Vaccines market, by product, 2015 - 2026 (USD Million)
-
Table Brazil Prophylactic Human Vaccines market, by application, 2015 - 2026 (USD Million)
-
Table Regulatory scenario
-
Table Mexico Prophylactic Human Vaccines market, by type, 2015 - 2026 (USD Million)
-
Table Mexico Prophylactic Human Vaccines market, by product, 2015 - 2026 (USD Million)
-
Table Mexico Prophylactic Human Vaccines market, by application, 2015 - 2026 (USD Million)
-
Table Regulatory scenario
-
Table Argentina Prophylactic Human Vaccines market, by type, 2015 - 2026 (USD Million)
-
Table Argentina Prophylactic Human Vaccines market, by product, 2015 - 2026 (USD Million)
-
Table Argentina Prophylactic Human Vaccines market, by application, 2015 - 2026 (USD Million)
-
Table MEA Prophylactic Human Vaccines market, by country, 2015 - 2026 (USD Million)
-
Table MEA Prophylactic Human Vaccines market, by type, 2015 - 2026 (USD Million)
-
Table MEA Prophylactic Human Vaccines market, by product, 2015 - 2026 (USD Million)
-
Table MEA Prophylactic Human Vaccines market, by application, 2015 - 2026 (USD Million)
-
Table Regulatory scenario
-
Table South Africa Prophylactic Human Vaccines market, by type, 2015 - 2026 (USD Million)
-
Table South Africa Prophylactic Human Vaccines market, by product, 2015 - 2026 (USD Million)
-
Table South Africa Prophylactic Human Vaccines market, by application, 2015 - 2026 (USD Million)
-
Table Regulatory scenario
-
Table Nigeria Prophylactic Human Vaccines market, by type, 2015 - 2026 (USD Million)
-
Table Nigeria Prophylactic Human Vaccines market, by product, 2015 - 2026 (USD Million)
-
Table Nigeria Prophylactic Human Vaccines market, by application, 2015 - 2026 (USD Million)
-
Table Recent Developments & Impact Analysis, by Key Market Participants
-
Table Recent Developments & Impact Analysis, by Key Market Participants
-
Table Company market position analysis
Table Company Profiles
Table BiondVax Pharmaceuticals Ltd. (Israel) Production, Value, Price, Gross Margin 2014-2019
Table Product benchmarking
Table Strategic initiatives
Table SWOT analysis
Table Company Profiles
Table Bavarian Nordic A/S (Denmark) Production, Value, Price, Gross Margin 2014-2019
Table Product benchmarking
Table Strategic initiatives
Table SWOT analysis
Table Company Profiles
Table Hualan Biological Engineering Inc. (China) Production, Value, Price, Gross Margin 2014-2019
Table Product benchmarking
Table Strategic initiatives
Table SWOT analysis
Table Company Profiles
Table Altimmune, Inc (US) Production, Value, Price, Gross Margin 2014-2019
Table Product benchmarking
Table Strategic initiatives
Table SWOT analysis
Table Company Profiles
Table GlaxoSmithKline Plc. (UK) Production, Value, Price, Gross Margin 2014-2019
Table Product benchmarking
Table Strategic initiatives
Table SWOT analysis
Table Company Profiles
Table Serum Institute of India Pvt Ltd (India) Production, Value, Price, Gross Margin 2014-2019
Table Product benchmarking
Table Strategic initiatives
Table SWOT analysis
Table Company Profiles
Table SK Chemicals Co., Ltd. (Korea) Production, Value, Price, Gross Margin 2014-2019
Table Product benchmarking
Table Strategic initiatives
Table SWOT analysis
Table Company Profiles
Table Zydus Cadila (India) Production, Value, Price, Gross Margin 2014-2019
Table Product benchmarking
Table Strategic initiatives
Table SWOT analysis
Table Company Profiles
Table Sanofi Pasteur SA (France) Production, Value, Price, Gross Margin 2014-2019
Table Product benchmarking
Table Strategic initiatives
Table SWOT analysis
Table Company Profiles
Table Shanghai BravoBio Co., Ltd. (China) Production, Value, Price, Gross Margin 2014-2019
Table Product benchmarking
Table Strategic initiatives
Table SWOT analysis
Table Company Profiles
Table Merck & Co., Inc. (US) Production, Value, Price, Gross Margin 2014-2019
Table Product benchmarking
Table Strategic initiatives
Table SWOT analysis
Table Company Profiles
Table BiondVax Pharmaceuticals Ltd (Israel) Production, Value, Price, Gross Margin 2014-2019
Table Product benchmarking
Table Strategic initiatives
Table SWOT analysis
Table Company Profiles
Table Bharat Biotech International Limited (India) Production, Value, Price, Gross Margin 2014-2019
Table Product benchmarking
Table Strategic initiatives
Table SWOT analysis
Table Company Profiles
Table Pfizer Inc. (US) Production, Value, Price, Gross Margin 2014-2019
Table Product benchmarking
Table Strategic initiatives
Table SWOT analysis
Table Company Profiles
Table Altimmune, Inc. (US) Production, Value, Price, Gross Margin 2014-2019
Table Product benchmarking
Table Strategic initiatives
Table SWOT analysis
Table Company Profiles
Table Serum Institute of India Pvt. Ltd. (India) Production, Value, Price, Gross Margin 2014-2019
Table Product benchmarking
Table Strategic initiatives
Table SWOT analysis
Table Company Profiles
Table Hualan Biological Engineering Inc (China) Production, Value, Price, Gross Margin 2014-2019
Table Product benchmarking
Table Strategic initiatives
Table SWOT analysis
Table Company Profiles
Table Janssen Pharmaceuticals, Inc. (US) Production, Value, Price, Gross Margin 2014-2019
Table Product benchmarking
Table Strategic initiatives
Table SWOT analysis
-
